ECI-830
- Generic Name
- ECI-830
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT06726148
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath